胃食管反流病患者中CYP2C19快代谢和超快代谢高患病率
单中心回顾性研究纳入2019至2024年门诊接受CYP2C19基因检测的421例胃食管反流病(GERD)患者,发现快代谢者占44%(n=184);
要点
- GERD患者中CYP2C19快代谢者占44%,比例较高。
- 超快代谢者Barrett食管/糜烂性食管炎风险高于正常代谢者。
- 依据CYP结果调整PPI后糜烂性食管炎缓解有改善趋势但未达显著。
核心结论
- 接受CYP2C19基因分型的GERD患者中很大比例为快代谢者,且根据结果调整PPI后反应良好。
研究设计与样本
- 单中心回顾性研究,纳入2019至2024年门诊接受CYP2C19检测的GERD患者421例。
主要发现
- 快代谢者(快代谢+超快代谢)患病率为44%(n=184)。
临床怎么用
- 对GERD患者可考虑CYP2C19基因检测以识别快代谢者。
- 根据CYP2C19结果调整PPI可能改善部分患者管理。
局限性
- 单中心回顾性设计,样本来自门诊特定人群。
- PPI调整与糜烂性食管炎缓解的关联未达统计学显著。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Gastroesophageal reflux disease (GERD) is one of the most diagnosed diseases in the United States. A large proportion of patients have an inadequate response to proton pump inhibitors (PPIs), despite the optimization of dosing and timing. We hypothesized that such an inadequate response is often due to polymorphisms in cytochrome P450 2C19 (CYP2C19, CYP). This study aimed to assess the prevalence of rapid CYP metabolism in patients with GERD. METHODS: We conducted a single-center retrospective study on patients in an outpatient gastroenterology clinic with GERD who underwent CYP testing between 2019 and 2024. We collected data on CYP genotype, PPI dosing before and after CYP testing, endoscopy results, pH testing, and documentation of symptomatic improvement. Rapid and ultrarapid metabolizers were grouped as "rapid metabolizers," whereas normal and intermediate metabolizers were grouped as "normal metabolizers." RESULTS: In total, 421 patients with GERD who underwent CYP testing were included in the study. The prevalence of rapid metabolizers was 44% (n =184). The prevalence of Barrett's esophagus/erosive esophagitis was higher among ultrarapid metabolizers (24%; n = 5/21) than among normal metabolizers (7%; n = 12/165; odds ratio, 3.5; 95% confidence interval, 1.1-11.5; P = .0371). There was a nonstatistically significant trend towards higher odds of erosive esophagitis resolution when PPI was adjusted based on CYP results (odds ratio, 9.3; 95% confidence interval, 1.0-90; P = .081). CONCLUSIONS: A large proportion of patients with GERD who underwent CYP2C19 genotyping were rapid metabolizers of CYP2C19 and responded well to changing/adjusting PPIs accordingly.
引用
- Creech L, King W, Kleehammer AC, et al. High Prevalence of CYP2C19 Rapid and Ultrarapid Metabolism Among Patients With Gastroesophageal Reflux Disease. Clin Gastroenterol Hepatol. 2025. PMID: 41197932. doi:10.1016/j.cgh.2025.10.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。